share_log

Design Therapeutics Analyst Ratings

Benzinga ·  Aug 15, 2023 20:00
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/15/2023 -4.5% RBC Capital $23 → $7 Downgrades Outperform → Sector Perform
05/10/2023 213.78% RBC Capital $24 → $23 Maintains Outperform
05/10/2023 159.21% Wedbush $20 → $19 Maintains Outperform
05/04/2023 Goldman Sachs Upgrades Sell → Neutral
03/15/2023 227.42% RBC Capital → $24 Reiterates → Outperform
12/09/2022 200.14% SVB Leerink $30 → $22 Maintains Outperform
12/08/2022 227.42% RBC Capital $29 → $24 Maintains Outperform
08/09/2022 254.71% Wedbush $21 → $26 Maintains Outperform
06/10/2022 186.49% Wedbush → $21 Initiates Coverage On → Outperform
05/24/2022 -18.14% Goldman Sachs $8 → $6 Maintains Sell
05/10/2022 309.28% SVB Leerink $36 → $30 Maintains Outperform
05/02/2022 309.28% RBC Capital → $30 Initiates Coverage On → Outperform
01/19/2022 36.43% Goldman Sachs → $10 Initiates Coverage On → Sell
04/20/2021 391.13% SVB Leerink → $36 Initiates Coverage On → Outperform
04/20/2021 281.99% Goldman Sachs → $28 Initiates Coverage On → Neutral
04/20/2021 472.99% Piper Sandler → $42 Initiates Coverage On → Overweight

What is the target price for Design Therapeutics (DSGN)?

The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on August 15, 2023. The analyst firm set a price target for $7.00 expecting DSGN to fall to within 12 months (a possible -4.50% downside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Design Therapeutics (DSGN)?

The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics downgraded their sector perform rating.

When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Is the Analyst Rating Design Therapeutics (DSGN) correct?

While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a downgraded with a price target of $23.00 to $7.00. The current price Design Therapeutics (DSGN) is trading at is $7.33, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment